DOCSLIB.ORG

The Enemies of Our Enemies 58 V

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
The Enemies of Our Enemies 58 V A Good Journal for Inquisitive People (46) scfh.ru/en/ 1 1 2017 SCIENCE First Hand PHAGES ATTACK № 1 (46) 2017 100 YEARS IN THE SERVICE OF MANKIND VIRUSES AND BACTERIA: THE GREAT CONFRONTATION PHAGEBIOTICS FOR A HEALTHY LIFE BACTERIOPHAGES This is how a filamentous bacteriophage looks like after counterstaining with phosphotungstic acid in the field of vision THE ENEMIES of a Jem 1400 (JEOL, Japan) electron microscope by E. Ryabchikova OF OUR ENEMIES 2017 1. popular science journal IN THIS ISSUE: Bacteriophages “won” the Battle of Stalingrad: they did not let a cholera epidemic spread outside the territory occupied by German troops If all bacteriophages on Earth line up in a single file, it will stretch as far as the nearest galaxy cluster in the constellation Virgo! Biologists learned to edit genomes by spotting how bacteria protect themselves from reinfection with bacteriophages Thanks to filamentous bacteriophages, we will soon have energy-conserving ultrathin displays Using bacteriophages instead of antibiotics will ensure that we eat organic food A Journal “The natural desire for Inquisitive People of good men is knowledge” Dear Friends, Editorial Board Editor-in-Chief Leonardo da Vinci This issue of our magazine commemorates the centennial RAS Member Nikolay Dobretsov Periodical Popular Science Journal of the discovery of bacteriophages. Bacteriophages Deputy Editor-in-Chief are minuscule viruses, but their role in science can hardly RAS Member Valery Bukhtiyarov Published since January 2004 be overestimated. Deputy Editor-in-Chief Three issues a year Viruses are known to be the smallest living organisms RAS Member Valentin Vlassov Founders: Siberian Branch of the Russian on Earth; there is even an opinion that calling them “alive” Deputy Editor-in-Chief Academy of Sciences (SB RAS) may be wrong as they have too simple a structure. In fact, RAS Corresponding Member Rzhanov Institute of Semiconductor Physics a virus is a genetic program encoded in DNA or RNA strands (SB RAS) Natalia Polosmak packed in a protein shell. Viral genes can work only inside Institute of Archaeology and Ethnography Deputy Editor-in-Chief (SB RAS) a living cell of another organism by embedding themselves RAS Member Vasily Shabanov Limnological Institute (SB RAS) into the host genome and forcing the cellular metabolic Executive Secretary Sobolev Institute of Geology and Mineralogy machine to produce new copies of viral particles. Like other Lidia Panfilova (SB RAS) viruses, bacteriophages (literally, «eaters of bacteria») Institute of Chemical Biology and are intracellular parasites, but they use bacteria and archaea, RAS Member Igor Bychkov Fundamental Medicine (SB RAS) rather than animals and plants, as their hosts. RAS Member Anatoly Derevyanko Trofimuk Institute of Oil and gas Geology and Geophysics (SB RAS) In recent years, we have learned that bacteriophages RAS Member Mikhail Epov Limited company INFOLIO play a huge role in the biosphere: controlling the amount RAS Corresponding Member Publisher: Limited company INFOLIO of microbial flora, they are a major factor hindering Mikhail Fedoruk Address: its unrestrained growth. No wonder that the quantity RAS Member Mikhail Grachev 11, Zolotodolinskaya Street, Novosibirsk of bacteriophages is enormous: their total biomass may However, the ingenious idea to fight bacteria with a living RAS Corresponding Member 630090, Russia be as high as 109 tons whereas the total mass of all living biological weapon has outlived its creators. For many years, Aleksandr Latyshev Tel. +7 (383) 330 37 33, 330 27 22 organisms is only an estimated 2–3 orders of magnitude the USSR had been the world center of bacteriophage Fax: +7 (383) 330 26 67 Cand. Sc. Nikolay Nikulin higher. Bacteriophages are not just the most common form research, and phage therapy passed its first major test during RAS Member Valentin Parmon e-mail: [email protected] of life on Earth: being an integral part of trophic cycles, they World War II. Suffice it to say that the cholera bacteriophage RAS Member Nikolay Pokhilenko [email protected] actively participate in the global cycle of matter and energy. was one the fighters in the famous Battle of Stalingrad. Since bacteriophages can target specific strains of bacteria, Produced directly in the besieged city of Stalingrad, this [email protected] Editorial Council mankind has used them, albeit with varying success, virus helped localize a cholera epidemic that broke out on the The Journal is registered as a very accurate and safe weapon against bacterial RAS Member Lyubomir Aftanas territory occupied by German troops. at the Federal Supervision Agency infections in humans and animals almost since the time RAS Member Boris Bazarov for Information Technologies and The subsequent history of phage therapy is an excellent they were discovered in the early twentieth century. illustration of the philosophical thesis that any development RAS Corresponding Member Communications The very history of this discovery reads like a fascinating follows a spiral path. In the 1980s, it became clear that the Evgeny Berezhko Certificate El No. FS77-37579 of September 25, 2009 novel, the main characters being two dramatic and tragic effectiveness of antibiotic treatment decreased dramatically RAS Member Vladimir Boldyrev personalities—a brilliant self-educated Frenchman Félix due to the increasing drug resistance to antibiotics. Scientists RAS Member Andrey Degermendzhi ISSN 2310-3000 Date of publication 20 May 2017 d’Hérelle and his closest associate and friend, a Georgian and physicians around the world turned their eyes, once Dr. Sc. Aleksandr Elert microbiologist George Eliava. again, to bacteriophages. After all, the unique advantage Open price RAS Corresponding Member The time when they lived and worked was an era of wars of phage drugs over antibiotics is their targeted action against Anatoly Fedotov Editorial Staff All rights reserved. Reproduction in part and revolutions, which shattered the very foundations or whole is allowed only with written a specific bacterial strain or species without damaging Dr. Sc. Mikhail Fokin A. Kharkevich authorization of the Editorial Office of society, but these two men were not of the kind to hide the normal microflora of the organism, which is why they Dr. Sc. Anatoly Kharitonov Cand. Sc. L. Ovchinnikova © Siberian Branch RAS, 2017 from reality in the ivory tower. Félix d’Hérelle, the discoverer can be used safely for prevention, as well as treatment, RAS Member Nikolay Kolchanov L. Panfilova of bacteriophages, who spent, at the age of seventy, of infections. © INFOLIO Publishing House, 2017 RAS Member Alexei Kontorovich Cand. Sc. M. Perepechaeva several years under house arrest for refusing to help the A. Mistrukov Of course, no one today argues categorically that, Professor Egon Krause (Germany) © Rzhanov Institute of Semiconductor German invaders, had to witness at the end of his life how E. Sycheva Physics (SB RAS) 2017 at the present stage in the development of science, RAS Member Gennadii Kulipanov A. Vladimirova his beloved child was losing ground to the increasing spread bacteriophages can completely replace other antibacterial Dr. Sc. Semen Kutateladze © Institute of Archaeology and Ethnography (SB RAS) 2017 of antibiotics. George Eliava, who declined an invitation preparations in medicine and agriculture, but all the articles RAS Member Mikhail Kuzmin Translated of the famous Pasteur Institute in Paris with the words in this issue clearly show that bacteriophages can into English by © Limnological Institute (SB RAS) 2017 Professor Janusz Lipkowski (Poland) “I’m needed in Georgia” and founded the world’s first and be for mankind not only a neighbor with whom we share one I. Adrianova RAS Member Nikolay Lyakhov © Sobolev Institute of Geology and only bacteriophage research center in Tbilisi, was shot in his A. Kobkova Mineralogy (SB RAS) 2017 biosphere but also a strong and loyal ally. RAS Member Vyacheslav Molodin home country as an “enemy of the people.” N. Tumanova © Institute of Chemical Biology and Dr. Sc. Mikhail Moshkin G. Chirikova Fundamental Medicine (SB RAS) 2017 RAS Corresponding Member © Trofimuk Institute of Oil and gas Geology Academician Nikolay L. Dobretsov, Sergei Netesov The drawings on the cover and Geophysics (SB RAS) 2017 Editor-in-Chief Dr. Sc. Aleksandr Petrov and inside RAS Member Anatoly Shalagin the journal RAS Member Vladimir Shumny are by Zhenya Professor Valery Soyfer (USA) Vlassov scfh.ru/en/ LIFE SCIENCES 50 A. A. Shiryaeva, A. V. Strotskaya, K. V. Severinov .01 6 V. V. Vlassov Viruses and bacteria: Bacteriophages – The great confrontation the enemies of our enemies 58 V. V. Vlassov, V. V. Morozova, TRANSPLANTING healthy fecal microflora 8 Under the sign of bacteriophage: Using BACTERIOPHAGES to combat PLANT N. V. Tikunova with a set of “GOOD” BACTERIA and “PROPER” Paris – Tbilisi DISEASES at greenhouse farms will allow farmers BACTERIOPHAGES into the intestine of a patient to grow large CROPS of ORGANIC vegetables The truth about phage therapy 22 T. V. Prisada, M. G. Efimova, or a memo to physicians and patients ensures an almost instantaneous treatment A. N. Dabizheva, N. N. Voroshilova and greens. P. 74 of DYSBACTERIOSIS. P. 58 Phages Attack. 66 A. Sulakvelidze Phagebiotics for a healthy life A history of bacteriophage production and therapeutic use in Russia 74 K. A. Miroshnikov Phages in your garden. 32 E. I. Ryabchikova, A. Yu. Yunusova Lythic PHAGES target PATHOGENIC bacteria, Phage drugs may be a good ALTERNATIVE
Load more

Recommended publications
  • Energy Efficiency And
    Progress with The Energy Policy Review: A Perspective OIES Seminars 7 October 2003 John Bower Overview What the White Paper Said Reality Dawns An alternative 20:20 Vision John Bower Progress on UK Energy White Paper 2 What the White Paper Said UKEWP refocused energy policy away from a UK driven liberalisation agenda… GOALS AND POLICIES 1. Reduce CO2 emissions by 60% by 2050 Reduce amount of energy we consume Central to future market and policy will be emissions trading Raise efficiency standards in home appliances and housing Encourage low carbon fuels and renewables through grants and subsidy 2. Maintain reliability of energy supplies Right infrastructure / regulatory systems in UK and liberalisation of Europe Pursue regional stability and economic reform in producing areas Promote understanding of markets and conditions for FDI in producing areas Forward prices will signal the need for investment Improve contingency planning in dealing with major incidents John Bower Progress on UK Energy White Paper 3 What the White Paper Said …. towards an EU driven multifaceted agenda GOALS AND POLICIES 3. Promote competitive markets in UK and beyond Raise rate of sustainable economic growth Support business and competitiveness through reliable / affordable energy Encourage firms to innovate, reduce cost, deliver better goods and services Use market based instruments to deliver policy goals Work with business to prepare them for the low carbon economy of the future 4. Ensure that every home is adequately and affordably heated Reduce poverty by lowering prices and raising social security payments Improve quality of housing stock via insulation and energy efficiency grants John Bower Progress on UK Energy White Paper 4 What the White Paper Said UKEWP relied on carbon trading and uneconomic/unproven technology… ENERGY SYSTEM IN 2020 1.
    [Show full text]
  • Therapeutic Efficacy of Bacteriophages Ramasamy Palaniappan and Govindan Dayanithi
    Chapter Therapeutic Efficacy of Bacteriophages Ramasamy Palaniappan and Govindan Dayanithi Abstract Bacteriophages are bacterial cell-borne viruses that act as natural bacteria killers and they have been identified as therapeutic antibacterial agents. Bacteriophage therapy is a bacterial disease medication that is given to humans after a diagnosis of the disease to prevent and manage a number of bacterial infections. The ability of phage to invade and destroy their target bacterial host cells determines the efficacy of bacteriophage therapy. Bacteriophage therapy, which can be specific or nonspecific and can include a single phage or a cocktail of phages, is a safe treat- ment choice for antibiotic-resistant and recurrent bacterial infections after antibi- otics have failed. A therapy is a cure for health problems, which is administered after the diagnosis of the diseases in the patient. Such non-antibiotic treatment approaches for drug-resistant bacteria are thought to be a promising new alterna- tive to antibiotic therapy and vaccination. The occurrence, biology, morphology, infectivity, lysogenic and lytic behaviours, efficacy, and mechanisms of bacterio- phages’ therapeutic potentials for control and treatment of multidrug-resistant/ sensitive bacterial infections are discussed. Isolation, long-term storage and recov- ery of lytic bacteriophages, bioassays, in vivo and in vitro experiments, and bacteri- ophage therapy validation are all identified. Holins, endolysins, ectolysins, and bacteriocins are bacteriophage antibacterial enzymes that are specific. Endolysins cause the target bacterium to lyse instantly, and hence their therapeutic potential has been explored in “Endolysin therapy.” Endolysins have a high degree of bio- chemical variability, with certain lysins having a wider bactericidal function than antibiotics, while their bactericidal activities are far narrower.
    [Show full text]
  • MI4A Vaccine Purchase Data for Countries This Note Is Intended to Guide Countries in Their Use of the MI4A Vaccine Purchase Data
    MI4A Vaccine Purchase Data for Countries This note is intended to guide countries in their use of the MI4A vaccine purchase data. What data is available? new vaccine introductions, but also for product switches – and to understand the status of product The WHO vaccine market intelligence database registrations. Fifty-six Member States responded compiles vaccine purchase (product, price and to these new questions. procurement) data as reported by countries via the WHO/UNICEF Joint Reporting Form (JRF) over the This information is essential to WHO’s efforts to period of 2013–2018. While country names are not improve global market forecasts and inform displayed, data is publicly available on the MI4A suppliers’ and global policy-makers’ investment website and provides information by country decisions. WHO encourages all countries to characteristics (e.g. region, income group…) by report information on new introduction plans and vaccine and by year of purchase, along with price planned product changes as well as to respond to per dose (USD), procurement mechanism and questions related to registration. annual volumes. 1 The number of countries reporting vaccine How can my country use this data? purchase data through the JRF continues to Countries can use the vaccine purchase data in increase year after year, with 182 Member States several different ways, such as to: (93%) reporting some vaccine procurement information in 2019 – including 158 (81%) fully • Understand how the price of vaccines in their reporting on vaccine purchase data. Price reporting immunization schedule relate to other this year marks a 3% increase from last year and products on the market, or compare the more than triple the reporting from 2016.
    [Show full text]
  • Contribution of Podoviridae and Myoviridae Bacteriophages
    www.nature.com/scientificreports OPEN Contribution of Podoviridae and Myoviridae bacteriophages to the efectiveness of anti‑staphylococcal therapeutic cocktails Maria Kornienko1*, Nikita Kuptsov1, Roman Gorodnichev1, Dmitry Bespiatykh1, Andrei Guliaev1, Maria Letarova2, Eugene Kulikov2, Vladimir Veselovsky1, Maya Malakhova1, Andrey Letarov2, Elena Ilina1 & Egor Shitikov1 Bacteriophage therapy is considered one of the most promising therapeutic approaches against multi‑drug resistant bacterial infections. Infections caused by Staphylococcus aureus are very efciently controlled with therapeutic bacteriophage cocktails, containing a number of individual phages infecting a majority of known pathogenic S. aureus strains. We assessed the contribution of individual bacteriophages comprising a therapeutic bacteriophage cocktail against S. aureus in order to optimize its composition. Two lytic bacteriophages vB_SauM‑515A1 (Myoviridae) and vB_SauP‑ 436A (Podoviridae) were isolated from the commercial therapeutic cocktail produced by Microgen (Russia). Host ranges of the phages were established on the panel of 75 S. aureus strains. Phage vB_ SauM‑515A1 lysed 85.3% and vB_SauP‑436A lysed 68.0% of the strains, however, vB_SauP‑436A was active against four strains resistant to vB_SauM‑515A1, as well as to the therapeutic cocktail per se. Suboptimal results of the therapeutic cocktail application were due to extremely low vB_SauP‑436A1 content in this composition. Optimization of the phage titers led to an increase in overall cocktail efciency. Thus, one of the efective ways to optimize the phage cocktails design was demonstrated and realized by using bacteriophages of diferent families and lytic spectra. Te wide spread of multidrug-resistant (MDR) bacterial pathogens is recognized by the World Health Organi- zation (WHO) as a global threat to modern healthcare1.
    [Show full text]
  • List of Registred Drugs in Armenia (01.03.2017-31.03.2017)
    LIST OF REGISTRED DRUGS IN ARMENIA (01.03.2017-31.03.2017) International nonproprietary name Dose and Registration Term of Legal Status N Trade name Drug form Manufacturer Country ATC1 code License holder (generic) or active packaging number registration for Supply ingredients name Eli Lilly Regional Lilly France S.A.S., Operations GmbH., solution for 100IU/ml, Zone Industrielle, 2 17.03.2017 1 Abasaglar insulin glargine France A10AE04 16535 PoM2 Koelblgasse 8-10, injection 3ml cartridges (5) rue du Colonel Lilly, 17.03.2022 1030, Vienna, 67640 Fegersheim Austria Olainfarm JSC, 5 300mg, Olainfarm JSC, 5 06.03.2017 Rupnicu Str., 2 Adaptol mebicar capsules hard in blister (20/2x10/, Rupnicu Str., Olaine, Latvia N06BX21 16440 PoM 06.03.2022 Olaine, LV-2114, 30/3x10/, 40/4x10/) LV-2114 Latvia Olainfarm JSC, 5 Olainfarm JSC, 5 500mg, 06.03.2017 Rupnicu Str., 3 Adaptol mebicar tablets Rupnicu Str., Olaine, Latvia N06BX21 16441 PoM in blister (20/2x10/) 06.03.2022 Olaine, LV-2114, LV-2114 Latvia 10mg, Pharmstandard- OTCPharm PJSC, fabomotizole in blisters Leksredstva JSC, 27.03.2017 123317, Moscow, 4 Afobazol (fabomotizole tablets (30/1x30/, 60/3x20/, 305022, Kursk, Russia N05BX04 14729/2 PoM 30.07.2020 Testovskaya str., 10, dihydrochloride) 60/2x30/, 90/3x30/, Agregatnaya 2nd str., Russia 120/4x30/) 1a/18 Gedeon Richter 15mg/g, Gedeon Richter PLC, 17.03.2017 PLC, Gyomroi ut 5 Airtal aceclofenac cream 60g aluminium Gyomroi ut 19-21, Hungary M01AB16 16514 OTC3 17.03.2022 19-21, 1103 tube 1103 Budapest Budapest, Hungary 1 Gedeon Richter PLC, Gyomroi ut 19-21, 1103 Budapest - batch releaser, Industrias Gedeon Richter Farmaceuticas powder for oral 100mg, 17.03.2017 PLC, Gyomroi ut 6 Airtal aceclofenac Almirall S.L., Ctra.
    [Show full text]
  • Chronic Bacterial Prostatitis Treated with Phage Therapy After Multiple Failed Antibiotic Treatments
    CASE REPORT published: 10 June 2021 doi: 10.3389/fphar.2021.692614 Case Report: Chronic Bacterial Prostatitis Treated With Phage Therapy After Multiple Failed Antibiotic Treatments Apurva Virmani Johri 1*, Pranav Johri 1, Naomi Hoyle 2, Levan Pipia 2, Lia Nadareishvili 2 and Dea Nizharadze 2 1Vitalis Phage Therapy, New Delhi, India, 2Eliava Phage Therapy Center, Tbilisi, Georgia Background: Chronic Bacterial Prostatitis (CBP) is an inflammatory condition caused by a persistent bacterial infection of the prostate gland and its surrounding areas in the male pelvic region. It is most common in men under 50 years of age. It is a long-lasting and Edited by: ’ Mayank Gangwar, debilitating condition that severely deteriorates the patient s quality of life. Anatomical Banaras Hindu University, India limitations and antimicrobial resistance limit the effectiveness of antibiotic treatment of Reviewed by: CBP. Bacteriophage therapy is proposed as a promising alternative treatment of CBP and Gianpaolo Perletti, related infections. Bacteriophage therapy is the use of lytic bacterial viruses to treat University of Insubria, Italy Sandeep Kaur, bacterial infections. Many cases of CBP are complicated by infections caused by both Mehr Chand Mahajan DAV College for nosocomial and community acquired multidrug resistant bacteria. Frequently encountered Women Chandigarh, India Tamta Tkhilaishvili, strains include Vancomycin resistant Enterococci, Extended Spectrum Beta Lactam German Heart Center Berlin, Germany resistant Escherichia coli, other gram-positive organisms such as Staphylococcus and Pooria Gill, Streptococcus, Enterobacteriaceae such as Klebsiella and Proteus, and Pseudomonas Mazandaran University of Medical Sciences, Iran aeruginosa, among others. *Correspondence: Case Presentation: We present a patient with the typical manifestations of CBP.
    [Show full text]
  • Annex 2 Composition of Oral and Injectable Estrogen–Progestogen Contraceptives
    ANNEX 2 COMPOSITION OF ORAL AND INJECTABLE ESTROGEN–PROGESTOGEN CONTRACEPTIVES Annex 2 lists the composition of brands of estrogen–progestogen preparations used in combined injectables (Table 1), combined oral (Table 2) and phasic oral (Table 3) contraceptives. The countries in which these formulations are used are noted. Are listed only those brands for which availability was reported. The source of these tables is the International Planned Parenthood Foundation (IPPF). Data have been taken from the IPPF 2002 website [http://contraceptive.ippf.org] at the time of the monograph meeting (June 2005). This online site is regularly updated. Table 1. Combined injectables Brand name Composition Countries of availability Acefil Dihydroxyprogesterone acetophenide 150 mg Paraguay + estradiol enanthate 10 mg Agurin Dihydroxyprogesterone acetophenide 150 mg Chile + estradiol enanthate 10 mg Anafertin Dihydroxyprogesterone acetophenide 75 mg El Salvador, Mexico + estradiol enanthate 5 mg Ciclofem Medroxyprogesterone acetate 25 mg Guatemala + estradiol cypionate 5 mg Ciclofemina Medroxyprogesterone acetate 25 mg El Salvador + estradiol cypionate 5 mg Ciclomes Dihydroxyprogesterone acetophenide 150 mg Paraguay + estradiol enanthate 10 mg Ciclovular Dihydroxyprogesterone acetophenide 150 mg Brazil + estradiol enanthate 10 mg Clinomin Dihydroxyprogesterone acetophenide 150 mg Paraguay + estradiol enanthate 10 mg Cyclofem Medroxyprogesterone acetate 25 mg Chile, Indonesia, Malaysia, Mexico, + estradiol cypionate 5 mg Panama, Zimbabwe Cyclofemina Medroxyprogesterone
    [Show full text]
  • BACTERIOPHAGE THERAPY Old Treatment, New Focus?
    The magazine of the Society for Applied Microbiology ■ June 2009 ■ Vol 10 No 2 ISSN 1479-2699 BACTERIOPHAGE THERAPY old treatment, new focus? ■ Antimicrobial resistance in bacterial enteric pathogens ■ Mediawatch: university press office ■ Summer conference 2009 ■ Engaging the public in infectious disease ■ Charles Darwin and microbes ■ Art, cybernetics and normal flora microbiology ■ An unwanted guest for dinner ■ Careers: sales manager ■ ■ INSIDE Statnote 16: using a regression line for prediction and calibration PECS: virtual networking excellence in microbiology Cultured bacteria will not be seen dead in it. Buy your next workstation from us. Designers and manufacturers of anaerobic and microaerobic workstations since 1980 / patented dual-function portholes for user access and sample transfer / automatic atmospheric conditioning system requiring no user maintenance / available in a range of sizes and capacities to suit the needs of every laboratory / optional single plate entry system Technical sales: +44 (0)1274 595728 www.dwscientific.co.uk June 2009 ■ Vol 10 No 2 ■ ISSN 1479-2699 contentsthe magazine of the Society for Applied Microbiology members 04 Editorial: the effective communication of science 05 Contact point: full contact information for the Society 06 Benefits: what SfAM can do for you and how to join us 07 President’s and CEO’s columns 09 Membership Matters 38 Careers: sales manager 40 An unwanted guest for dinner 42 In the loop: news from PECS — virtual networking 20 43 Research Development Grant report 45 Students into Work grant reports 49 President’s Fund articles news 12 MediaWatch: the university press office 14 Med-Vet-Net: workpackage 34 28 32 publications The beauty of bacteria Charles Darwin and microbes 11 JournalWatch features information Microbiologist is published quarterly by the Society for Bacteriophage therapy: old treatment, new focus Applied Microbiology.
    [Show full text]
  • Vaccine Purchase Data and Cover Note for Countries
    MI4A Vaccine Purchase Data for Countries The MI4A Vaccine Purchase How can my country use this data?1 Database What data is available? • • • • WORKING DOCUMENT - MI4A Vaccine Purchase Data Note [December 2020] | 1 Immunization Agenda IA 2030 Reporting Vaccine Purchase Data Documenting use of MI4A data WORKING DOCUMENT - MI4A Vaccine Purchase Data Note [December 2020] | 2 Key messages to countries • • • 7 WORKING DOCUMENT - MI4A Vaccine Purchase Data Note [December 2020] | 3 • • • • • . / WORKING DOCUMENT - MI4A Vaccine Purchase Data Note [December 2020] | 4 • • • • • • • 12 WORKING DOCUMENT - MI4A Vaccine Purchase Data Note [December 2020] | 5 • • • • • • • • 13 WORKING DOCUMENT - MI4A Vaccine Purchase Data Note [December 2020] | 6 • • • • • WORKING DOCUMENT - MI4A Vaccine Purchase Data Note [December 2020] | 7 What is MI4A? • • • WORKING DOCUMENT - MI4A Vaccine Purchase Data Note [December 2020] | 8 A. Available Products List - as known to WHO The MI4A Products List provides a snapshot overview of vaccine products available for procurement – irrespective of their WHO prequalification status – as of November 2020. This list reflects information reported by countries through the 2020 Joint Reporting Form (JRF) and is supplemented with available information gathered through separate consultations. As part of the MI4A project, WHO conducts in-depth global market studies where the list of available vaccines can be considered comprehensive and up to date. Studies conducted so far include BCG, D&T-containing, measles-containing, meningococcal, HPV, pneumococcal, rabies, and typhoid vaccines. For all the other vaccines it should be noted that this list may not be complete and may be missing some products whose availability is not documented through public reported data and sources.
    [Show full text]
  • Biotechnology in Russia: Why Is It Not a Success Story?
    Biotechnology in Russia: Why is it not a success story? Biotechnology inRussia:Whyisitnotasuccessstory? ROGER ROFFEY Biotechnology in Russia: Why is it not a success story? According to President Medvedev 2009 ‘By and large, our industry continues to make the same outdated products and, as a rule, imported generics from substances bought abroad. There is practically no work to create original medicines and technologies.’…‘We must begin the modernisation and technological upgrading of our entire industrial sector. I see this as a question of our country’s survival in the modern world’… ‘These are the key tasks for placing Russia on a new technological level and making it a global leader’. Many states including Russia see biotechnology and its commercialization as a key driver for their future growth. The biotechnology area is characterized by being a very knowledge-intensive activity where there is increasing global competition for know-how. Russia had a very good historical base of R&D and know- how in biotechnology from the previous Soviet military programme. There have been many attempts since 2000 to revive the Russian biotechnology industry not least in 2005 but without much success. In 2009 there were again very ambitious programmes and strategies developed as well as techno-parks for the ROGERROFFEY development of the biotechnology and pharmaceuticals industry up to 2020. It has also been announced by President Medvedev the creation of a Russian equivalent to ‘Silicon Valley’ to include R&D also in biotechnology outside Moscow. There have been many such grand plans but so far they have not been very successful and the question for this study was if it would be different this time? Why are scientists still leaving Russia and foreign investors still hesitating to invest in Russian biotechnology or pharmaceuticals? Why is Russia still not able to compete on the global biotechnology market and is ranked only as number 70 in the world? The current problems and prospects for the biotechnology and pharmaceuticals industries are analysed.
    [Show full text]
  • PR-Bird Flu-CCX-[MASTER]
    Avian Flu D-125TM H5N1 It's not a matter of if... it's a matter of WHEN BELIEVED BY US EPA TO KILL AVIAN FLU D-125 is a US EPA-registered sanitizer, disinfectant and cleaner effective against several strains of the Avian Flu. The US EPA does not currently have any products that are regis- tered against the particular H5N1 strain of Avian Flu; however, the US EPA has indicated that they believe D-125 will prove effective against H5N1 once testing is completed. These products are available in an economical concentrate and ready-to-use spray and wipe formulation. Both the concentrate and the ready-to-use are US EPA-registered to kill an extraor- dinary range of 120 plus microbial organisms including all of the pan-demic human influenza strains of the 20th century including: Influenza A / Brazil Virus Influenza A / Victoria (H3N2) Virus Influenza A2-Asian Virus Influenza B Virus (Allen Strain) Influenza C Virus (Taylor Strain) D-125 is a registered tademark of Microgen Inc. Parainfluenza Type 1 In addition to being among a select group of products believed effective against H5N1 Avian Flu Virus, D-125 registered for use in and has specific instructions for disinfecting poultry houses as well as meat, poultry and food processing plants. Microgen Inc. D-125 is also registered for use on both hard, non-porous Clinton Square Executive Center surfaces and on porous surfaces. West Caldwell, NJ 07006 USA www.microgeninc.com With such versatility and efficacy D-125 is the ultimate choice 1-800-420-7522 or 973-575-9025 when disinfecting and sanitizing.
    [Show full text]
  • Live Attenuated Influenza Vaccines Against
    ccines & a V f V a o c l c i a n n a Larionova et al., J Vaccines Vaccin 2013, 4:8 r t u i o o n DOI: 10.4172/2157-7560.1000208 J Journal of Vaccines & Vaccination ISSN: 2157-7560 Research Article Open Access Live Attenuated Influenza Vaccines against Highly Pathogenic H5N1avian Influenza: Development and Preclinical Characterization Natalie Larionova1*, Irina Kiseleva1, Irina Isakova-Sivak1, Andrey Rekstin1, Irina Dubrovina1, Ekaterina Bazhenova1, Ted M Ross2, David Swayne3, Larisa Gubareva4, Vadim Tsvetnitsky5, Ekaterina Fedorova1, Elena Doroshenko1 and Larisa Rudenko1 1Institute of Experimental Medicine, St. Petersburg, Russia 2University of Pittsburgh, Pittsburgh, PA, USA 3Southeast Poultry Research Laboratory, Athens, GA, USA 4Centers for Disease Control and Prevention, Atlanta, GA, USA 5PATH (Program for Appropriate Technologies in Health), USA Abstract In this paper we describe the development and the outcomes of the preclinical studies of temperature-sensitive and cold-adapted candidates for live attenuated influenza vaccine (LAIV) based on highly pathogenic avian influenza viruses A/H5N1 with pandemic potential. The LAIV candidates were developed by methods of classical re- assortment between H2N2 Master Donor Virus for Russian LAIV and H5N1 viruses generated by reverse genetics for inactivated vaccine. These reverse genetically generated viruses were chosen as a source of H5 hemagglutinin and contained a modified protease cleavage site believed to be associated with high virulence. The progeny of re- assortment had 7:1 gene composition and were characterized by antigen specificity of the HA of the pandemic virus, a high growth rate in chicken embryos and their parameters of temperature sensitivity and cold adaptation confirmed preserved attenuation of the Master Donor Virus.
    [Show full text]